XT
CDTX

XTX Topco’s Cidara Therapeutics CDTX Stock Holding History

XTX Topco’s Portfolio CDTX Stock Details CDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-8,512
Closed -$415K – 2636
2025
Q2 		$415K Buy
+8,512
New +$205K 0.02% 1231
2024
Q2 		– Sell
-3,951
Closed -$72.7K – 1925
2024
Q1 		$72.7K Sell
3,951
-4,102
-51% -$58.9K 0.01% 1409
2023
Q4 		$128K Sell
8,053
-2,085
-21% -$33.5K 0.03% 1075
2023
Q3 		$191K Sell
10,138
-12,319
-55% -$242K 0.03% 1028
2023
Q2 		$508K Buy
22,457
+15,015
+202% +$353K 0.09% 360
2023
Q1 		$189K Buy
+7,442
New +$211K 0.04% 975
2022
Q1 		– Sell
-1,972
Closed -$50K – 699
2021
Q4 		$50K Buy
+1,972
New +$61.4K 0.03% 567
2021
Q3 		– Sell
-1,299
Closed -$52K – 730
2021
Q2 		$52K Buy
+1,299
New +$55K 0.02% 727

Other funds holding CDTX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

XTX Topco's CDTX Position: Q3 2025 in Review

XTX Topco sold out of Cidara Therapeutics (CDTX) in Q3 2025, closing a stake of 8,512 shares — an estimated $415K sold.

XTX Topco first reported a position in CDTX in Q2 2021 and held it in 8 quarters. The position peaked at $508K in Q2 2023. 173 funds tracked by Wall St. Rank hold CDTX as of Q3 2025.

  • XTX Topco reported no remaining Cidara Therapeutics position as of Q3 2025 after selling out during the quarter.
  • XTX Topco sold 8,512 Cidara Therapeutics shares in Q3 2025, an estimated $415K.
  • XTX Topco first reported a position in Cidara Therapeutics in Q2 2021 and held it in 8 quarters.
  • XTX Topco's Cidara Therapeutics position peaked at $508K in Q2 2023.
  • 173 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q3 2025.

Based on XTX Topco's 13F filing for Q3 2025, filed 14 Nov 2025.